Nuvalent Presents New Preclinical Data For HER2-Selective Inhibitor, NVL-330, And ROS1-Selective Inhibitor, Zidesamtinib, At AACR Annual Meeting 2024
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to be effective at suppressing on-target ROS1 resistance mutations in preclinical mutagenesis screens